Introduction
Mitochondria, the main generators of cellular energy, are under the dual genetic control of both the mitochondrial genome (mtDNA) and nuclear DNA. The mitochondrial genome, a small 16.6-kb molecule, encodes 13 subunits of the respiratory chain complexes, as well as 22 tRNAs and two ribosomal RNAs required for intramitochondrial synthesis. 1 It is the only extrachromosomal DNA present in human cells, present at high copy number and is highly organised, exhibiting little redundancy of its coding sequence. Owing to a lack of protective histone protein, a relative lack of repair capacity and its close proximity to the respiratory chain and the reactive oxygen species (ROS) they generate, the mitochondrial genome is particularly vulnerable to mutation. 2, 3 Over the last decade, mtDNA mutations have been increasingly recognised as important causes of maternally inherited neurological and multisytem disease. 4, 5 In a recent epidemiology survey, pathogenic mtDNA mutations have been shown to be present in at least one in 8000 of the population. 6 Many pathogenic mutations affect a proportion of mtDNA copies within a cell, resulting in a mixture of mutated and wild-type genomes -a situation termed heteroplasmy. 7 Mutations may be homoplasmic, affecting all copies of the mitochondrial genome within a cell. 8 In addition to inherited mtDNA defects, it has been proposed that acquired mtDNA mutations play an important role in both ageing and certain degenerative conditions. 9, 10 In older individuals, clonal expansion of individual mtDNA mutations leading to a focal biochemical defect within individual cells has been demonstrated. 11 Alternative mechanisms for this clonal expansion have been suggested, 12 but recent mathematical modelling studies suggest that it may be due to random genetic drift. 13 The mechanisms by which somatic mutations occur and accumulate have recently been discussed in detail. 14 In 1998, Vogelstein and colleagues described the finding of somatic mtDNA point mutations in human colorectal tumours that were absent in the normal, healthy tissues from the same individuals. The importance of these mutations to the development of cancer remains uncertain. 16, 17 Unlike those found in ageing that lead to a measurable biochemical deficit within the cell, many of these mutations are homoplasmic, occur at nonconserved sites within mtDNA and are therefore considered unlikely to have any effect on mitochondrial function. Since the original report by Polyak et al, 15 numerous studies have shown that somatic mtDNA mutations are present in many different tumour types.
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The incidence and role of somatic mutations in acute and chronic leukaemia have not been explored. However, pathogenic mtDNA mutations have been reported in some patients with myelodysplastic syndrome, particularly those with ringed sideroblasts. [22] [23] [24] [25] A screen of the entire mitochondrial genome in patients with myelodysplasia has revealed clonal mutations in approximately one-third of patients, 25 including well-characterised pathogenic mtDNA mutations 24 and mutations in cytochrome c oxidase (CO) structural genes that have been shown to induce a biochemical defect. 23 We therefore decided to determine the spectrum of somatic mtDNA mutation in adultonset leukaemia by comparing directly the entire mitochondrial genome sequence from normal and leukaemic cells obtained from 24 patients with both chronic and acute presentations.
Materials and methods

Patients
We studied a total of 24 adult patients (aged 18-88 years), six with acute lymphatic leukaemia (ALL), six with acute myeloid leukaemia (AML), six with chronic lymphatic leukaemia (CLL) and six with chronic myeloid leukaemia (CML) ( Table 1 ). All gave their informed consent for these investigations, which were approved by the local Ethics Committee. Tumour samples were represented by bone marrow (ALL and AML), blood with high white blood cell count (CLL) or blood during therapy failure (CML). For each patient, buccal epithelial cells were collected from mouthwashes by centrifugation as representative of normal tissue.
mtDNA sequencing
DNA was extracted by standard procedures and the entire mitochondrial genome was amplified in 28 overlapping frag-ments of between 600 and 700 bp using M13-tagged oligodeoxynucleotide primers to facilitate the direct sequencing of the PCR-amplified products. A complete list of the primer pairs and sequencing protocol has been published previously. 26 Briefly, following PCR amplification, samples were purified to remove unincorporated primers and sequenced directly using BigDye terminator cycle sequencing chemistries (PE Biosystems) on an ABI 377 automated DNA sequencer. The sequences obtained were compared directly to the revised Cambridge reference sequence (rCRS) 27 using Sequence Navigator and Factura software (PE Biosystems) to identify sequence variants. Somatic mutations were identified by directly comparing the sequence differences detected in buccal and tumour samples from individual patients. Available DNA template was limited for some of the bone marrow samples and, in such cases, a two-stage strategy was employed to amplify the complete mitochondrial genome exactly as previously described. 26 Analysis of the A15296G cytochrome b mutation in different tissues and disease states Last hot cycle PCR-RFLP analysis, a widely used technique in the study of patients with pathogenic mtDNA mutations, 8 was initially used to detect and quantify the relative proportions of mutated and wild-type mtDNA genotypes in samples from the patient with the A15269G transition as follows. Mismatch primers were used to engineer recognition sites for the restriction endonuclease Hsp92II into the amplified products. Both oligonucleotide primers were M13 tailed (sequence shown in lower case) and recognised the following sequences: light strand (15084-15105), tgtaaaacgacggccagtGAAACATCGGCAT-GATCCTCC; and heavy strand (15319-15297), caggaaacagctatgaccGGCTGCAATAATGAAGGGCAACA (mismatch nucleotides shown in bold). The mismatches in both primers generate Hsp92II restriction sites in the wild-type PCR product, cutting the 272 bp amplimer into three fragments of 201, 39 and 32 bp.
In the presence of the A15296G transition, one of these Hsp92II sites is lost, resulting in restriction fragments of 240 and 32 bp.
The relative proportions of wild-type and mutant mtDNA genomes in different samples were determined by the addition of 5 mCi [a-
32 P]-dCTP (3000 Ci/mmol) prior to the last cycle of the PCR. Labelled products were digested with 10 U Hsp92II, separated through a 12% nondenaturing polyacrylamide gel, and the radioactivity in each fragment quantified using ImageQuant software (Molecular Dynamics).
We also developed an allele-specific real-time PCR assay employing the SYBR green dye to determine accurately the amount of mutated and wild-type mtDNA copies in samples Table 1 Clinical details of patients with adult-onset leukaemia 0 -CTGCAATAATGAAGGGCAAGGC-3 0 )). Prior to quantifying the level of the A15296G mutation, we constructed a standard curve for both wild-type and mutant mtDNA using cloned wild-type and mutant templates. Briefly, PCR reactions (20 ml volume) were monitored in a Lightcycler s (Roche) using Faststart DNA Master SYBR Green1 and a final concentration of 5 mM MgCl 2 ; all primers were at a final concentration of 0.5 mM. Following an initial cycle (951C for 10 min) to denature the target DNA and to activate the polymerase, samples were subjected to 45 cycles of amplification as follows: 951C for 10 s, 641C for 5 s and 721C for 10 s. The fluorescence signal obtained was measured at the end of the elongation phase. Additionally, melting curve analyses were performed after each PCR to assess the specificity of the amplified products. The Ct value and logarithm of the starting copy number have a good correlation, and the standard curves of wild-type and mutant reaction were obtained.
For quantification of the G15296 allele, the patient's buccal DNA sample (10 ng/ml) and different stages of the patient's bone marrow sample were amplified simultaneously in wild-type and mutant reactions by SYBR Green real-time PCR (see above). The initial copy numbers of wild-type and mutant mtDNA molecules in these samples were calculated based on Ct value and the formula, which was obtained from the standard curves of the wild-type (Y ¼ À3.583x þ 37.462) and mutant reactions (Y ¼ À3.73x þ 38.871). The data represented in Figure 1 were obtained from three separate experiments, each with three independent observations.
Results
mtDNA sequence analysis
We compared the entire sequence of the mitochondrial genome from normal (buccal epithelium) and leukaemic cells from each of the 24 leukaemia patients. In each patient there were a number of changes from the revised rCRS for human mtDNA 27 that were present in both buccal and leukaemia samples (see supplementary table on the journal website), a finding that is consistent with the natural variation in mitochondrial genome sequences evident within a normal population. 28 In nine of the 24 patients there was an additional single, somatic mtDNA mutation, which was only present in the tumour sample (Table 2) . These somatic mutations were present in both acute and chronic forms of leukaemia and were located throughout the genome, in the noncoding control region and coding region. With the exception of the C4T mutation in patient 6, which was clearly heteroplasmic, all the other somatic mutations appeared homoplasmic (only mutated mtDNA genotype) on the sequence electropherogram. Although only two (G14569A and G16129A) of the nine mutations have previously been reported on databases of human mtDNA polymorphic variants (see http://www.mitomap.org and http://www.genpat.uu.se/mtDB/), it is unlikely that any of these mutations have a major effect on mitochondrial function as they are either silent changes (eg C13848T in patient 7) or predict very conservative amino-acid substitutions. For example, the A15296G mutation in patient 2 predicts an isoleucine to valine change at codon 184 of the cytochrome b gene, a residue that shows poor evolutionary conservation. 29 
mtDNA mutations at different stages of disease activity
We had the opportunity to study in detail further samples at different stages of disease in one of our ALL patients in whom we had detected an mtDNA mutation (A15296G) only in the leukaemia (Figure 1a) . Using last hot cycle PCR-RFLP analysis, we quantified the level of the mutated mtDNA in buccal cell DNA and total bone marrow DNA extracted from biopsy material taken at the time of original presentation, during chemotherapy-induced haematological remission and at the time of relapse (Figure 1b, c) . We show that although high levels of the A15296G mutation were present in the bone marrow at initial presentation, the mutant genotype appears to be lost in haematological remission, and reappears when the patient relapses. As the level of detection of this assay is approximately 1% mutant genotype, we subsequently developed a mismatch real-time PCR-based assay that allows us to detect at least at the level of 0.1% of mutated mtDNA in a background of normal DNA (Figure 1d) . With this assay, we were able to show that mutated mtDNA was present at low levels even in the bone marrow at the time of initial haematological remission, which is entirely compatible with the subsequent relapse in this patient. Table 2 Somatic mtDNA mutations in patients with adult-onset leukaemia
Patient
Clinical diagnosis mtDNA mutation detected Gene Amino-acid change
Sequence of the entire mitochondrial genome from 24 paired samples (normal, buccal epithelia and tumour) was determined and compared to the rCRS for human mtDNA. The base substitutions shown were only present in the leukaemic tissue at apparently homoplasmic levels, with the exception of C4T (*) which was heteroplasmic. Ile, isoleucine; Leu, leucine; Phe, Phenylalanine; Pro, proline; Ser, serine; Val, valine.
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Discussion
We have determined that somatic mtDNA mutations are present in a proportion of patients with adult-onset leukaemia by sequencing the entire mitochondrial genome from normal and leukaemic cells. Our studies have shown that in our cohort of patients, approximately 40% show evidence of a somatic mtDNA mutation that is only present in the leukaemia. All the mutations we detected were single-nucleotide substitutions, which were homoplasmic in all but one patient who harboured a somatic C4T mutation at a level of about 40% in leukaemic cells (patient 6, Table 2) , well above the level of detection for mtDNA heteroplasmy that has been estimated at 25-30% mutated mtDNA by direct sequencing. 26, 28 Considering that the overwhelming majority of the mutations we observed were present at homoplasmy, we believe it is unlikely that a significant proportion of somatic mutations are undetected by this technique. Moreover, our observations are similar to the results obtained from the analysis of colorectal and other tumours in which somatic mtDNA mutations are also present only in a percentage of patients. [17] [18] [19] [20] [21] Our study is entirely different from that performed by Ivanova et al, 30 who studied mtDNA sequence variability in 30 French patients with ALL (adults and children) by RFLP analysis, but did not specifically look for somatic mtDNA mutations. They found nucleotide substitutions in leukaemia from 11 patients when compared to blood DNA from a group of healthy control individuals. However, recent studies from several laboratories have shown that there is extensive sequence variation within populations, and thus any sequence change between patient and control groups is likely to simply reflect this variation and as such is not evidence of somatic mtDNA mutation. 28 Our results are very similar to those obtained in patients with myelodysplasia in which somatic mtDNA mutations have also been described. [22] [23] [24] Gatterman et al 25 recently reported their investigations of patients with acquired sideroblastic anaemia and myelodysplasia by the complete analysis of the mitochondrial genome in 30 patients. They reported that clonal mtDNA mutations were detected in at least one-third of myelodysplasia patients. In those patients who were available for further studies, the clonal mutation was present in blood and bone marrow cells, but not in buccal mucosa or skin fibroblasts. Other researchers have also studied patients with myelodysplasia, but they did not directly compare normal and leukaemia mtDNA sequences from the same patient. 31, 32 While in both myelodysplasia and leukaemia there are somatic mtDNA mutations, there is a fascinating difference in the nature of the mutations detected. The mutations we detected in leukaemia are predicted to have little, if any, effect on mitochondrial function. In myelodysplasia however, the mutations detected include well-characterised, pathogenic mutations such as the A8344G MERRF mutation 24 or affect highly conserved nucleotides within tRNA genes. 22 Some of the mutations have been reported in structural subunits of the respiratory chain, and modelling of these mutations in transmitochondrial cybrid cell lines has confirmed their ability to cause mitochondrial dysfunction. 33 The reason for these differences in the somatic mutations in leukaemia and myelodysplasia is not known. However, in both conditions it is possible that the bone marrow has been populated by a stem cell clone with a replicative advantage that also contains a somatic mtDNA mutation. If the clone contains a mutation that has little effect on mitochondrial function, then there will be little inhibition of cell proliferation and leukaemia may develop. However, if the clone contains a pathogenic mtDNA mutation and cell function is impaired, myelodysplasia and sideroblastic anaemia may result. This would also be compatible with the observation that sideroblastic anaemia and myelodysplasia are well-recognised clinical features in some patients with mtDNA disease. 34 The study of marrow samples taken at different times during disease from patient 2 by real-time PCR indicates that the A15296G mutation observed in the presentation and relapse marrow samples is a clonal marker for the leukaemia. In the presence of such somatic mtDNA mutations, it may be possible therefore to devise sensitive tests to detect and monitor the leukaemia during treatment. Surprisingly, the total number of mtDNA genomes (ie wild-type plus mutated mtDNA) present in the relapse marrow appears much lower than that seen in either the presentation or remission marrow samples (Figure 1d ). While technical variation between samples cannot be ruled out as a cause for this phenomenon, these data suggest that the total number of mitochondrial genomes present at different stages in the disease may be different as a function of total cellular DNA content. This observation clearly warrants additional investigation, and our continuing studies will address this issue.
In conclusion, we have detected mtDNA mutations in patients with adult-onset leukaemia, although the mechanism and importance of mtDNA mutations remains uncertain. Further studies are required to determine at what stage the somatic mtDNA mutation occurs and this should give us an important insight into the role of somatic mtDNA mutations in both leukaemia and myelodysplasia.
